Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Deferred Revenue: 2016-2024

Historic Current Deferred Revenue for Collegium Pharmaceutical (COLL) over the last 4 years, with Dec 2024 value amounting to $191.5 million.

  • Collegium Pharmaceutical's Current Deferred Revenue fell 99.66% to $667,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $667,000, marking a year-over-year decrease of 99.66%. This contributed to the annual value of $191.5 million for FY2024, which is 27.82% up from last year.
  • Collegium Pharmaceutical's Current Deferred Revenue amounted to $191.5 million in FY2024, which was up 27.82% from $149.8 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Current Deferred Revenue registered a high of $191.5 million during FY2024, and its lowest value of $149.8 million during FY2023.
  • Moreover, its 3-year median value for Current Deferred Revenue was $156.9 million (2022), whereas its average is $166.1 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first fell by 4.53% in 2023, then increased by 27.82% in 2024.
  • MRY analysis of 3 years shows Collegium Pharmaceutical's Current Deferred Revenue stood at $156.9 million in 2022, then fell by 4.53% to $149.8 million in 2023, then grew by 27.82% to $191.5 million in 2024.
  • Its Current Deferred Revenue stands at $191.5 million for FY2024, versus $149.8 million for FY2023 and $156.9 million for FY2022.